{"id":1181,"date":"2026-09-27T10:00:00","date_gmt":"2026-09-27T10:00:00","guid":{"rendered":"https:\/\/medycyna-gorska.pl\/?p=1181"},"modified":"2026-09-27T10:08:23","modified_gmt":"2026-09-27T10:08:23","slug":"hypertension-high-altitude","status":"publish","type":"post","link":"https:\/\/medycyna-gorska.pl\/en\/hypertension-high-altitude\/","title":{"rendered":"Hypertension and high-altitude trekking \u2014 medications, monitoring, safety"},"content":{"rendered":"\n

Hypertension and high-altitude trekking<\/strong> is an important topic affecting ~30% of the 50+ population. Good news: controlled hypertension does NOT exclude<\/strong> expeditions to 5500 m. Bad news: altitude raises blood pressure by 10\u201320 mmHg, some antihypertensives lose efficacy, and some increase HAPE risk. This article: physiology, safe and risky medications, field BP monitoring protocol, when to cancel the expedition.<\/p>\n\n\n\n

In a nutshell \u2014 hypertension and altitude<\/h2>\n\n\n\n
    \n
  • Controlled hypertension<\/strong> (<140\/90 on medication) \u2014 compatible with trekking to 5500 m<\/li>\n
  • Altitude raises BP<\/strong> by 10\u201320 mmHg via sympathetic activation and endothelin<\/li>\n
  • Safe medications:<\/strong> ACE inhibitors (ramipril, enalapril), ARBs (losartan), long-acting nifedipine \u2014 bonus: HAPE prophylaxis<\/li>\n
  • Risky medications:<\/strong> beta-blockers (reduce acclimatization capacity), diuretics (dehydration risk)<\/li>\n
  • Monitoring:<\/strong> wrist BP cuff ($25\u201340), measurements 2\u00d7 daily<\/li>\n
  • Contraindications:<\/strong> poorly controlled hypertension, values >180\/110, recent MI, heart failure<\/li>\n<\/ul>\n\n\n\n

    How altitude affects blood pressure<\/h2>\n\n\n\n

    Mechanism \u2014 sympathetic activation<\/h3>\n\n\n\n

    Hypoxia activates carotid body chemoreceptors, which stimulate the sympathetic nervous system. Effect: increased catecholamine release (adrenaline, noradrenaline), vasoconstriction, accelerated heart rate. Systolic BP typically rises 10\u201320 mmHg, diastolic 5\u201310 mmHg. The effect persists for weeks to months at altitude \u2014 without full adaptation like ventilation.<\/p>\n\n\n\n

    Endothelin-1 and vasoconstriction<\/h3>\n\n\n\n

    Hypoxia stimulates endothelin-1 release from endothelial cells \u2014 a potent peripheral vasoconstrictor. The same mechanism underlies HAPE (pulmonary artery constriction) and peripheral arteriole constriction in fingers\/ears in cold. In a hypertensive patient this is an additional pathophysiological element increasing risk.<\/p>\n\n\n\n

    Polycythemia \u2014 blood viscosity<\/h3>\n\n\n\n

    After 2\u20134 weeks above 4000 m, hematocrit rises from 42% to 55\u201365%. Better oxygenation, but blood becomes viscous \u2014 increasing peripheral resistance and BP. This is the main reason why on long expeditions (Everest, Aconcagua) hypertension can worsen even on appropriate medication.<\/p>\n\n\n\n

    Antihypertensives \u2014 which to choose for expedition<\/h2>\n\n\n\n

    ACE inhibitors (recommended)<\/h3>\n\n\n\n
      \n
    • Ramipril 5\u201310 mg\/day<\/strong>, enalapril 10\u201320 mg\/day<\/strong>, lisinopril 10\u201320 mg\/day<\/strong><\/li>\n
    • Mechanism:<\/strong> block RAAS, vasodilate, don’t affect acclimatization<\/li>\n
    • Additional benefits:<\/strong> cardioprotection, anti-inflammatory effect<\/li>\n
    • Side effects:<\/strong> dry cough (5\u201315%), hyperkalemia (rare)<\/li>\n
    • Note:<\/strong> if you’re on an ACEi \u2014 continue unchanged<\/li>\n<\/ul>\n\n\n\n

      ARBs (sartans, alternative to ACEi)<\/h3>\n\n\n\n
        \n
      • Losartan 50\u2013100 mg\/day<\/strong>, telmisartan 40\u201380 mg\/day<\/strong>, valsartan 80\u2013160 mg\/day<\/strong><\/li>\n
      • Advantages:<\/strong> like ACEi but no cough; cardioprotection, nephroprotection<\/li>\n
      • Good for expeditions<\/strong> \u2014 often better tolerated than ACEi during prolonged exertion<\/li>\n<\/ul>\n\n\n\n

        Long-acting nifedipine (double-duty)<\/h3>\n\n\n\n
          \n
        • Nifedipine XL\/Retard 30\u201360 mg\/day<\/strong> or amlodipine 5\u201310 mg\/day<\/strong><\/li>\n
        • Double benefit:<\/strong> lowers systemic BP AND is HAPE prophylaxis (reduces pulmonary vascular resistance)<\/li>\n
        • Ideal choice<\/strong> for hypertensive patient planning expedition >4000 m<\/li>\n
        • Side effects:<\/strong> ankle edema, headaches at treatment initiation<\/li>\n<\/ul>\n\n\n\n

          Beta-blockers (with caution)<\/h3>\n\n\n\n
            \n
          • Bisoprolol, metoprolol, nebivolol<\/strong> \u2014 most commonly used<\/li>\n
          • Problem:<\/strong> reduce maximum exertional heart rate (HRmax), impairing altitude exertion tolerance<\/li>\n
          • Mechanism:<\/strong> beta-blockers block compensatory tachycardia, body can’t increase O\u2082 delivery proportionally to exertion<\/li>\n
          • Decision:<\/strong> if beta-blocker is for cardiological indication (post-MI, atrial fibrillation) \u2014 continue and limit expeditions to 3500\u20134000 m; if only for BP \u2014 switch to ACEi\/ARB 2 months before expedition<\/li>\n<\/ul>\n\n\n\n

            Diuretics (very cautious)<\/h3>\n\n\n\n
              \n
            • Hydrochlorothiazide, indapamide, furosemide<\/strong><\/li>\n
            • Problem:<\/strong> increase dehydration risk (hydration is already a challenge on expedition)<\/li>\n
            • Risk:<\/strong> hypokalemia, electrolyte disturbances, dehydration + increased blood viscosity (hematocrit)<\/li>\n
            • Decision:<\/strong> switch to ACEi\/ARB before expedition; if necessary \u2014 reduce dose 50%, monitor urine (color)<\/li>\n<\/ul>\n\n\n\n

              Blood pressure monitoring in the field<\/h2>\n\n\n\n
                \n
              • Wrist BP cuff<\/strong> (Omron, Microlife) \u2014 $25\u201340, light (150 g), runs on 2\u00d7 AAA<\/li>\n
              • Protocol:<\/strong> morning on waking before exertion and evening at camp, 2 measurements 2 min apart, take median<\/li>\n
              • Target on expedition:<\/strong> <150\/95 (less strict than at sea level)<\/li>\n
              • Red flag:<\/strong> >180\/110, headaches + dizziness, visual disturbances \u2014 signal of hypertensive crisis, evacuation<\/li>\n
              • False elevation:<\/strong> cold, stress, exertion \u2014 wait 10 min in warm tent before measurement<\/li>\n<\/ul>\n\n\n\n

                When NOT to go high altitude<\/h2>\n\n\n\n
                  \n
                • Poorly controlled hypertension<\/strong> (>160\/100 on current medication)<\/li>\n
                • Myocardial infarction within 6 months<\/strong><\/li>\n
                • Heart failure<\/strong> (EF <50%, NYHA II+)<\/li>\n
                • Uncontrolled atrial fibrillation<\/strong> with rapid ventricular response<\/li>\n
                • Hypertensive retinopathy<\/strong> grade III\/IV<\/li>\n
                • Kidney failure<\/strong> (GFR <60) \u2014 risk of deterioration<\/li>\n<\/ul>\n\n\n\n

                  In these cases: cardiology consultation, expeditions to 2500\u20133000 m, avoid >4000 m.<\/p>\n\n\n\n

                  Frequently asked questions<\/h2>\n\n\n
                  \n
                  \n
                  \n

                  Can I climb Kilimanjaro on a beta-blocker?<\/h3>\n
                  \n\n

                  Yes, with caveats. Kilimanjaro 5895 m on beta-blocker is possible, but expect: 1) lower exertion tolerance (HRmax reduced 20-30 bpm); 2) slower acclimatization (less compensatory ventilation); 3) more fatigue. Recommendation: switch to ACEi\/ARB 2 months before expedition IF beta-blocker is only for BP. If post-MI or atrial fibrillation – continue beta-blocker, but extend Kilimanjaro schedule by 1-2 days (e.g. 8 days instead of 6).<\/p>\n\n<\/div>\n<\/div>\n

                  \n

                  Does amlodipine (calcium channel blocker) help with HAPE?<\/h3>\n
                  \n\n

                  Yes, at least theoretically. Nifedipine SL\/retard 30 mg is standard HAPE prophylaxis (B\u00e4rtsch 2005) – pulmonary artery vasodilation. Amlodipine 5-10 mg\/day acts similarly, though fewer studies in this indication. If amlodipine is your BP medication – continue, you get bonus HAPE prophylaxis. Absolutely: don’t stop nifedipine\/amlodipine before expedition. If your doctor wants to switch you 3 months before expedition >4000 m – ask to keep amlodipine or add nifedipine as HAPE prophylaxis.<\/p>\n\n<\/div>\n<\/div>\n

                  \n

                  I have hypertension and take HCT. Can I do EBC?<\/h3>\n
                  \n\n

                  Yes, but swap HCT. Hydrochlorothiazide is a diuretic increasing water and electrolyte loss. On expedition: 1) dehydration is already a problem (dry air, intense breathing, difficult water access); 2) hypokalemia further weakens muscles; 3) blood viscosity rises via polycythemia – additional dehydration worsens rheology. Recommendation: cardiology consultation 3 months pre-expedition, switch HCT to losartan 50 mg or ramipril 5 mg. EBC is safe on that medication.<\/p>\n\n<\/div>\n<\/div>\n

                  \n

                  How much does BP rise at 5000 m?<\/h3>\n
                  \n\n

                  Typically systolic 10-20 mmHg, diastolic 5-10 mmHg above sea-level values. Mechanism: sympathetic activation by hypoxia (carotid body chemoreceptors), elevated catecholamines, vasoconstriction (endothelin-1). Effect persists throughout altitude stay – does NOT adapt like ventilation. In a well-controlled hypertensive patient this means targeting ~140\/90 instead of 125\/80 sea level. Hence target <150\/95 on expedition is realistic.<\/p>\n\n<\/div>\n<\/div>\n

                  \n

                  I have hypertensive crisis during trek – what to do?<\/h3>\n
                  \n\n

                  Crisis (BP >180\/110 + symptoms: headaches, dizziness, visual disturbances, dyspnea, chest pain) is life-threatening. Protocol: 1) Lie down immediately, elevate legs, breathe calmly. 2) If you have captopril SL (Capoten 25 mg) – sublingual, effect in 15-30 min. 3) Oxygen if available. 4) Satellite\/heli evacuation – this is NOT a walk-out situation. 5) Don’t give furosemide as first choice (too aggressive). In hypertensive patient’s kit always: captopril SL 25 mg (3-4 tablets).<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n

                  References<\/h2>\n\n\n\n
                    \n
                  • Parati G, Revera M, Giuliano A, et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure<\/em>. Eur Heart J. 2013;34(10):759\u2013766.<\/li>\n
                  • Mingji C, Onakpoya IJ, Perera R, et al. Relationship between altitude and the prevalence of hypertension<\/em>. Heart. 2015;101(13):1054\u20131060.<\/li>\n
                  • Wilderness Medical Society 2019 Guidelines.<\/li>\n
                  • ESC\/ESH 2023 Guidelines for the management of arterial hypertension.<\/li>\n<\/ul>\n\n\n\n

                    Note:<\/strong> A patient with hypertension requires cardiology consultation 3 months before a high-altitude expedition, possible medication changes and continuous monitoring. This article is informational. Emergency numbers: 112, TOPR +48 601 100 300.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"

                    Hypertension and high-altitude expedition: safe medications (ACEi, ARB, nifedipine), risky ones (beta-blockers, diuretics), BP monitoring protocol.<\/p>\n","protected":false},"author":2,"featured_media":801,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-1181","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medycyna-gorska"],"_links":{"self":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/comments?post=1181"}],"version-history":[{"count":2,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1181\/revisions"}],"predecessor-version":[{"id":1418,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1181\/revisions\/1418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/media\/801"}],"wp:attachment":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/media?parent=1181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/categories?post=1181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/tags?post=1181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}